These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 14677465)

  • 21. Heart failure in rheumatoid arthritis: rates, predictors, and the effect of anti-tumor necrosis factor therapy.
    Wolfe F; Michaud K
    Am J Med; 2004 Mar; 116(5):305-11. PubMed ID: 14984815
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Etanercept therapy in children with juvenile rheumatoid arthritis.
    Hung JJ; Huang JL
    J Microbiol Immunol Infect; 2005 Dec; 38(6):444-6. PubMed ID: 16341346
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Etanercept-associated SLE with lupus nephritis.
    Neradová A; Stam F; van den Berg JG; Bax WA
    Lupus; 2009 Jun; 18(7):667-8. PubMed ID: 19433471
    [No Abstract]   [Full Text] [Related]  

  • 24. Treatment of rheumatoid arthritis with etanercept.
    Genovese MC; Kremer JM
    Rheum Dis Clin North Am; 2004 May; 30(2):311-28, vi-vii. PubMed ID: 15172043
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Etanercept].
    Mühlhäuser U; Münzel F; Eschenhagen T
    Dtsch Med Wochenschr; 2003 Aug; 128(34-35):1775-8. PubMed ID: 12934172
    [No Abstract]   [Full Text] [Related]  

  • 26. Treatment of myositis with etanercept (Enbrel), a recombinant human soluble fusion protein of TNF-alpha type II receptor and IgG1.
    Sprott H; Glatzel M; Michel BA
    Rheumatology (Oxford); 2004 Apr; 43(4):524-6. PubMed ID: 15024139
    [No Abstract]   [Full Text] [Related]  

  • 27. The trials of anakinra.
    Burls A; Jobanputra P
    Lancet; 2004 Sep 4-10; 364(9437):827-8. PubMed ID: 15351176
    [No Abstract]   [Full Text] [Related]  

  • 28. Do etanercept-naive patients with rheumatoid arthritis respond better to infliximab than patients for whom etanercept has failed?
    Yazici Y; Erkan D
    Ann Rheum Dis; 2004 May; 63(5):607-8; author reply 608. PubMed ID: 15082503
    [No Abstract]   [Full Text] [Related]  

  • 29. Tumor necrosis factor-alpha blockade and the risk of vasculitis.
    Guillevin L; Mouthon L
    J Rheumatol; 2004 Oct; 31(10):1885-7. PubMed ID: 15468348
    [No Abstract]   [Full Text] [Related]  

  • 30. Increase in plasma levels of adiponectin after administration of anti-tumor necrosis factor agents in patients with rheumatoid arthritis.
    Nagashima T; Okubo-Fornbacher H; Aoki Y; Kamata Y; Kimura H; Kamimura T; Nara H; Iwamoto M; Yoshio T; Okazaki H; Minota S
    J Rheumatol; 2008 May; 35(5):936-8. PubMed ID: 18464318
    [No Abstract]   [Full Text] [Related]  

  • 31. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T; Forslid J; van Vollenhoven A; Harju A; Brannemark S; Klareskog L; van Vollenhoven RF
    Ann Rheum Dis; 2004 Sep; 63(9):1075-8. PubMed ID: 15066863
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Atrial fibrillation occurring in a patient taking etanercept plus methotrexate for rheumatoid arthritis.
    Wooten MD; Reddy GV; Johnson RD
    Del Med J; 2000 Dec; 72(12):517-9. PubMed ID: 11200291
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Occurrence of cold agglutinin disease in RA patient during etanercept therapy successfully treated with rituximab.
    Malesci D; La Montagna G
    Rheumatology (Oxford); 2008 May; 47(5):734-5. PubMed ID: 18326535
    [No Abstract]   [Full Text] [Related]  

  • 34. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y; Markovits D; Rozin A; Toledano K; Nahir AM; Balbir-Gurman A
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Successful short term treatment of patients with severe undifferentiated spondyloarthritis with the anti-tumor necrosis factor-alpha fusion receptor protein etanercept.
    Brandt J; Khariouzov A; Listing J; Haibel H; Sörensen H; Rudwaleit M; Sieper J; Braun J
    J Rheumatol; 2004 Mar; 31(3):531-8. PubMed ID: 14994401
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Two is better than one? Combination therapy in rheumatoid arthritis.
    Choy EH
    Rheumatology (Oxford); 2004 Oct; 43(10):1205-7. PubMed ID: 15226519
    [No Abstract]   [Full Text] [Related]  

  • 37. Coarctation of the aorta in an infant exposed to etanercept in utero.
    Hemmati I; Stephanie E; Shojania K
    J Rheumatol; 2009 Dec; 36(12):2848. PubMed ID: 19966200
    [No Abstract]   [Full Text] [Related]  

  • 38. Breast lymphoma complicating anti-tumor necrosis factor therapy in rheumatoid arthritis.
    Pattanaik D; Koduru S; Azouz A; Patil S; Carbone L
    Clin Breast Cancer; 2011 Dec; 11(6):413-6. PubMed ID: 21729669
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Case report: Response in proteinuria due to AA amyloidosis but not Felty's syndrome in a patient with rheumatoid arthritis treated with TNF-alpha blockade.
    Ravindran J; Shenker N; Bhalla AK; Lachmann H; Hawkins P
    Rheumatology (Oxford); 2004 May; 43(5):669-72. PubMed ID: 15103032
    [No Abstract]   [Full Text] [Related]  

  • 40. Safety of combination therapy with rituximab and etanercept for patients with rheumatoid arthritis.
    Blank N; Max R; Schiller M; Briem S; Lorenz HM
    Rheumatology (Oxford); 2009 Apr; 48(4):440-1. PubMed ID: 19153143
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.